lupus nephritis

Advertisement
Richard Furie, MDNephrology Times | June 11, 2025
Richard Furie discusses new data from BLISS-LN supporting the efficacy and safety of belimumab for active proliferative LN.
Charlotte RobinsonNephrology Times | June 3, 2025
In the phase 3 REGENCY trial, adding obinutuzumab to standard therapy for lupus nephritis led to better renal outcomes.
Freely FilteredNephrology Times | June 11, 2025
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Charlotte RobinsonNephrology Times | February 20, 2025
Researchers studied osteoporosis prevalence and risk factors in Chinese patients with lupus nephritis.
Charlotte RobinsonNephrology Times | December 23, 2024
The American College of Rheumatology issued a summary of a new guideline for lupus nephritis.
Charlotte RobinsonNephrology Times | November 13, 2024
The Lupus Foundation of America will honor Brad H. Rovin, MD, and Alí Duarte-García, MD, at the Evelyn V. Hess Reception.
Charlotte RobinsonASN Kidney Week 2024 | October 14, 2024
Lupkynis for lupus nephritis is the focus of six accepted abstracts at the American Society of Nephrology Kidney Week 2024.
Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 17, 2024
A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.
Advertisement